Esperion Therapeutics (NASDAQ:ESPR – Free Report) had its price objective lowered by The Goldman Sachs Group from $4.00 to $3.00 in a research report report published on Thursday morning ...

In a report released today, Serge Belanger from Needham maintained a Buy rating on Esperion (ESPR – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.20.

Esperion (ESPR) host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership ...

The latest analyst rating for Esperion Therapeutics (NASDAQ:ESPR) was provided by Goldman Sachs, and Esperion Therapeutics maintained their neutral rating. The last upgrade for Esperion ...

ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 ...